Attached files
file | filename |
---|---|
EX-99.1 - Protagenic Therapeutics, Inc.\new | v179363_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of
Report (Date of Earliest Event Reported): March 30, 2010
ATRINSIC,
INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
001-12555
|
06-1390025
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification No.)
|
469
7th
Avenue, 10th Floor,
New York, NY 10018
(Address
of Principal Executive Offices/Zip Code)
(212)
716-1977
(Registrant’s
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions ( see
General Instruction A.2. below):
|
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Item
2.02.
|
Results of
Operations and Financial Condition
|
On March
30, 2009, Atrinsic, Inc. (the “Company”), issued a press release announcing its
2009 fourth quarter and full year financial results, a copy of which is attached
hereto as Exhibit 99.1.
The
information in this Item 2.02 of the Company’s Current Report on Form 8-K,
including Exhibit 99.1, is furnished pursuant to Item 2.02 and shall not be
deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of
1934, nor shall it be deemed incorporated by reference in any filing under the
Securities Act of 1933, except as shall be expressly set forth by specific
reference in such filing.
In
addition to historic information, this report, including Exhibit 99.1, contains
forward-looking statements regarding events, performance and financial trends.
Various factors could affect future results and could cause actual results to
differ materially from those expressed in or implied by the forward-looking
statements. Some of those factors are identified in Exhibit 99.1, and in our
periodic reports filed with the Securities and Exchange Commission.
Item 9.01.
|
Financial Statements and
Exhibits
|
|
(d)
|
Exhibits.
|
The
following exhibit is filed herewith:
Exhibit
|
||
Number
|
Description
|
|
99.1
|
Press
release issued by Atrinsic, Inc., dated March 30,
2010.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Atrinsic, Inc. | |||
Date:
March 30, 2010
|
By:
|
/s/ Thomas Plotts
|
|
Thomas
Plotts
|
|||
Interim
Chief Financial Officer
|